Le Lézard
Classified in: Health, Business
Subjects: LIC, FVT

Canary Health® Assists New Mexicans With Chronic Health Conditions, Like Diabetes


LOS ANGELES, April 10, 2018 /PRNewswire/ -- Canary Health, a national leading digital therapeutics company, and the New Mexico Retiree Health Care Authority (NMRHCA) are collaborating to offer the Better Choices, Better Health® (BCBH) digital therapeutics program in New Mexico. The goal is to increase access to and use of self-management resources for adults with one or more chronic health conditions, like diabetes and heart disease, and to improve quality of life and health outcomes.

www.nmrhca.org  New Mexico Retiree Health Care Authority

David Archuleta, Executive Director at NMRHCA stated, "Offering BCBH helps advance our mission and we are pleased to hear the encouraging stories of people taking more control of their health.  We're thankful for the collaboration with Canary Health, and for the support of our health plan partners making this program a success."

Preliminary results of the program report of NMRHCA members who participated in BCBH, 79% were more confident that they could manage their chronic condition(s), 82% felt that BCBH was easy to use and easy to understand, and most would recommend BCBH to a friend or loved one.

Cecilia Sena, a participant in BCBH and a member of NMRHCA, describes her experience as, "When you retire you realize how active you were before retirement because your pain becomes more evident. Better Choices, Better Health and the program's facilitators helped me learn to cope, get active, and stay healthy."

Currently the statewide collaboration rolling out BCBH includes the NMRHCA, Presbyterian Health Plan, Humana, Blue Cross and Blue Shield of New Mexico, and True Health New Mexico.

Adam Kaufman PhD, CEO, Canary Health shared, "Impacting health requires innovative collaborations. To have a multi-level partnership from the state, public employers and carriers all working together with the common goal of assisting participants with chronic conditions is unprecedented." He added, "Past published studies have shown that patients with type 2 diabetes had a decreased A1C of 1.27% at 12 months when their initial A1C was greater than 9%, and had reduced incidence of depression by 27%."

Kaufman will be presenting at the upcoming Interagency Benefits Advisory Committee (IBAC) held in Albuquerque on Wednesday, April 11th, where he will share results from the recent NMRHCA collaboration. The NMRHCA is one of four entities comprising the IBAC (the Risk Management Division, Retiree Health Care Authority, Public School Insurance Authority, and Albuquerque Public Schools).

NMRHCA members can enroll in the BCBH program by going to https://enroll-nmrhca.selfmanage.org/. For more information about Canary Health's BCBH program, visit www.canaryhealth.com/bcbh.

About Canary Health
Canary Health, a leading digital therapeutics company, offers programs that empower individuals with chronic conditions.  We work with the largest healthcare organizations in North America offering programs proven to slow the progression of chronic conditions, enhance quality of life, improve health outcomes, and lower the cost of care.

www.canaryhealth.com | www.facebook.com/canaryhealth | www.twitter.com/canaryhealth

About Canary Health's Better Choices, Better Health ® (BCBH)
BCBH is an online six-week workshop facilitated by trained peer coaches.  Participants reflect on how their life is impacted by their health and work to set personal action plans.  They receive support from their peers, and coaches.  BCBH has been proven to improve self-confidence, quality of life, and health outcomes and to lower healthcare utilization and costs.

Canary Health Contact
Carrie Pittman
(310)-444-0636 x 130
[email protected]

 

Canary Health

SOURCE Canary Health


These press releases may also interest you

at 02:22
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024 First Quarter 2024 Total revenue increased 19 per cent, 20 per cent at constant exchange rates, (CER)1, to SEK 6,256 M (5,239)Haematology revenue...

at 02:05
AstraZeneca: Revenue and EPS summary     Q1 2024 % Change $m Actual CER1 - Product Sales 12,177 15 18 - Alliance Revenue   457 59 59...

at 02:00
Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at...

at 02:00
In response to the increasing complexities of the aging journey and the rising trend of...

at 02:00
PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and...

at 02:00
Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood...



News published on and distributed by: